SIG 1451

Drug Profile

SIG 1451

Alternative Names: SIG1451

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator Signum Biosciences
  • Class Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; Signal transduction pathway inhibitors; Toll-like receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atopic dermatitis

Most Recent Events

  • 15 Feb 2017 Preclinical trials in Atopic dermatitis in USA (Topical) (Signum Biosciences pipeline, February 2016)
  • 15 Feb 2017 Signum Biosciences receives SBIR phase IIB grant from NIAID for SIG 1451 development in Atopic dermatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top